NASDAQ$PHVS
Pharvaris NV · Q2 2025 earnings
Q2 2025 earnings · · Investor relations
Briefing
Pharvaris Q2 2025: €45.5M net loss; RAPIDe-3 topline data expected in Q4 after $201M raise
Pharvaris N.V. reported second-quarter 2025 financial results for the period ended June 30, 2025, with no product revenue as a clinical-stage biopharmaceutical company. Net loss was €45.5 million versus €29.7 million in Q2 2024, with basic and diluted loss per share of €0.83. Research and development expenses were €29.6 million in the quarter and €60.5 million in the first half. Cash and cash equivalents totaled €200 million at June 30, 2025, extended by a subsequent approximately $201 million public offering in July that management expects will fund operations into the first half of 2027. The company anticipates RAPIDe-3 topline results for on-demand HAE treatment in Q4 2025, continues enrolling CHAPTER-3 prophylaxis trial with readout expected in H2 2026, and plans to initiate the CREAATE AAE-C1INH Phase 3 study by year-end 2025.
- Q2 net loss €45.5M ($0.83 loss per share); R&D expenses €29.6M in the quarter
- Cash and equivalents €200M at June 30; July offering added ~$201M extending runway into 1H2027
- RAPIDe-3 pivotal HAE on-demand study topline data anticipated in Q4 2025
- CHAPTER-3 prophylaxis Phase 3 enrollment ongoing; topline expected H2 2026
- CREAATE AAE-C1INH Phase 3 study on track to initiate by year-end 2025
Headline financials
Revenue & EPS history
Pharvaris · Revenue · Quarterly
€0
Forward guidance
Pharvaris expects RAPIDe-3 topline results in Q4 2025 as a key inflection point, CHAPTER-3 topline in H2 2026, and CREAATE study initiation by year-end 2025, supported by cash runway into 1H 2027 after the July 2025 offering.
Tailwinds
- RAPIDe-3 reached target enrollment in March 2025 with Q4 2025 readout anticipated
- Oversubscribed ~$201M offering strengthens balance sheet for late-stage programs
Headwinds
- Continued operating losses with Q2 net loss of €45.5M as trials advance
- Multiple pivotal programs still pre-commercial with regulatory timelines ahead
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 13 quarterly earnings reports · overlaid with Q2 2025
+16.7%
Avg return
Earnings day
+16.1%
Avg return
5 days after
+27.4%
Avg return
30 days after
36%
5 / 14 earnings
Positive
+243.4%
Q3 2022
Best reaction
-10.4%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.4% | +1.5% | +7.3% | |
| Q3 2025 | +7.3% | +3.3% | +0.2% | |
| Q4 2024 | -10.4% | -9.2% | +29.0% | |
| Q3 2024 | +3.6% | +5.4% | -7.3% | |
| Q4 2023 | -3.6% | -12.9% | -7.3% | |
| Q3 2023 | +9.3% | +2.7% | +9.9% | |
| Q2 2023 | -3.9% | -1.4% | +11.6% | |
| Q4 2022 | -5.2% | -2.0% | +9.0% | |
| Q3 2022 | +243.4% | +241.4% | +376.1% | |
| Q2 2022 | -2.7% | -2.1% | -46.3% | |
| Q4 2021 | -0.8% | -0.4% | -1.1% | |
| Q3 2021 | -0.2% | -0.8% | -6.8% | |
| Q2 2021 | -2.4% | -1.8% | +18.0% | |
| Q1 2021 | +0.0% | +1.2% | -8.7% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro